Is B-Raf a good therapeutic target for melanoma and other malignancies?
- PMID: 18172288
- DOI: 10.1158/0008-5472.CAN-07-2038
Is B-Raf a good therapeutic target for melanoma and other malignancies?
Abstract
The RAF family members, A-Raf, B-Raf, and C-Raf (or Raf-1), are intermediate molecules in the mitogen-activated protein (MAP) kinase [Ras/Raf/MAP kinase/extracellular signal-regulated kinase (Erk) kinase (MEK)/Erk] pathway, which relays extracellular signals from the cell membrane to the nucleus via a cascade of phosphorylation events ultimately promoting cancer development. This pathway is activated by mutation in approximately 7% of all human cancers. B-Raf is one of the proteins frequently mutated to an active form during tumor development. Therefore, B-Raf is an attractive cancer target but lack of clinical efficacy using agents targeting this protein has raised serious doubts about its therapeutic utility. Design of more effective B-Raf inhibitory agents, targeting other members of the signaling cascade for greater clinical efficacy or inhibiting B-Raf in combination with other targets, is being evaluated to resolve these perplexing issues. Here, we discuss recent progress, using preclinical models and clinical studies, to resolve the controversy of whether B-Raf would be a good therapeutic target for melanoma and other malignancies.
Similar articles
-
RKTG sequesters B-Raf to the Golgi apparatus and inhibits the proliferation and tumorigenicity of human malignant melanoma cells.Carcinogenesis. 2008 Jun;29(6):1157-63. doi: 10.1093/carcin/bgn119. Epub 2008 May 29. Carcinogenesis. 2008. PMID: 18515281
-
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.Semin Oncol. 2006 Aug;33(4):392-406. doi: 10.1053/j.seminoncol.2006.04.002. Semin Oncol. 2006. PMID: 16890795 Review.
-
Raf: a strategic target for therapeutic development against cancer.J Clin Oncol. 2005 Sep 20;23(27):6771-90. doi: 10.1200/JCO.2005.08.036. J Clin Oncol. 2005. PMID: 16170185 Review.
-
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.Oncogene. 2007 May 14;26(22):3291-310. doi: 10.1038/sj.onc.1210422. Oncogene. 2007. PMID: 17496923 Review.
-
Targeting the mitogen-activated protein kinase pathway in the treatment of malignant melanoma.Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2371s-2375s. doi: 10.1158/1078-0432.CCR-05-2539. Clin Cancer Res. 2006. PMID: 16609061 Review.
Cited by
-
Identification of aurora kinase B and Wee1-like protein kinase as downstream targets of (V600E)B-RAF in melanoma.Am J Pathol. 2013 Apr;182(4):1151-62. doi: 10.1016/j.ajpath.2012.12.019. Epub 2013 Feb 12. Am J Pathol. 2013. PMID: 23416158 Free PMC article.
-
A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors.Int J Mol Sci. 2015 May 29;16(6):12307-23. doi: 10.3390/ijms160612307. Int J Mol Sci. 2015. PMID: 26035757 Free PMC article.
-
Characterization and performance of nucleic acid nanoparticles combined with protamine and gold.Biomaterials. 2009 Nov;30(32):6451-9. doi: 10.1016/j.biomaterials.2009.07.067. Epub 2009 Sep 1. Biomaterials. 2009. PMID: 19726081 Free PMC article.
-
Melanoma prevention using topical PBISe.Cancer Prev Res (Phila). 2011 Jun;4(6):935-48. doi: 10.1158/1940-6207.CAPR-10-0202. Epub 2011 Mar 2. Cancer Prev Res (Phila). 2011. PMID: 21367959 Free PMC article.
-
Efficacy of IGFBP7 for treatment of metastatic melanoma and other cancers in mouse models and human cell lines.Mol Cancer Ther. 2009 Nov;8(11):3009-14. doi: 10.1158/1535-7163.MCT-09-0470. Epub 2009 Oct 27. Mol Cancer Ther. 2009. PMID: 19861408 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous